Drug Delivery Leader’s Post

● Pharma with Miremad ○ The average R&D cost to progress an asset from discovery to launch has remained flat for 2022–2023 at $2.3 billion per asset, reflecting an expanded range of assets and line extensions. ○ Reference: Deloitte (Measuring the return from pharmaceutical innovation – 14th edition) #researchanddevelopment #pharmaceutical #Pharma #marketresearch #pharmawithmiremad #deloitte #innovation #investment #businessdevelopment #ROI #Drugdiscovery

In this on-demand webinar, our panel of experts discusses key findings from a survey of 150 leaders at #biotech and #pharmaceutical organizations around the world. Listen in to explore the implications of these trends for #drugdevelopers, and gain insights into R&D strategies and new technologies. » https://bit.ly/471cn4v

Top 10 Pharma Industry Trends To Watch in 2024 Continued dominance of small molecule drugs Increasing adoption of biologics Outsourcing of drug development and manufacturing  Growing demand for personalized medicine  Increasing focus on emerging markets  Regulatory compliance  Increasing R&D costs  Supply chain management  Obtaining intellectual property  High costs of medications Any more inputs to the list ....

Interesting read on R&D, biotech, Pharma, policy and drug pricing. Carving out a vibrant and successful biomedical ecosystem. #policy #research #drug https://lnkd.in/gwuGiDmy

Title: Exploring the Drug Research and Development Journey Are you curious about the intricate process behind bringing life-saving drugs to market? Dive into the dynamic world of pharmaceutical research and development (R&D) with me! From initial discovery to regulatory approval, each stage demands meticulous attention to detail, innovative thinking, and unwavering dedication. Let's explore the fascinating journey of drug development, where science meets compassion to transform lives. #DrugDevelopment #Pharmaceuticals #Innovation

In less than 24 hours since the opening of the #PharmaSynergy #Networking_platform, our dynamic #BD & #Licensing executives have already initiated 498 #meeting_requests. This remarkable activity speaks to the proactive approach of the #BDteams, eagerly seizing the opportunity to #collaborate with their peers. The shared #Rx_focus among participating companies further fuels this enthusiasm. #PharmaSynergy is taking place on February 8-9 – so NOW is a perfect time to #join. Beyond #Rx_focused_partnering, #PharmaSynergy distinguishes itself by delivering #BDtuned_content, ensuring that companies not only engage in fruitful collaborations but also #stay_ahead in industry insights. We are delighted to introduce Ole Wiborg, CEO of Zerion Pharma, who will shed light on #innovative_technologies aimed at enhancing the #formulation of #poorly_soluble_drugs on February 8th. Zerion Pharma is a pharmaceutical development company aspiring to #transform the pharmaceutical landscape with a #new_formulation_technology, #Dispersome®, that enables #poorly_soluble_drugs to reach their true therapeutic potential.

The Medchem synthetic route to a new drug like molecule with a degree of optimization is good as long as the molecule is in the pre-clinical stage, however when it comes to the development stage, the molecule needs a different pair of eyes to arrive at the pharmaceutical route and that's where pharmaceutical route scouting comes as a critical stage in the drug development process, demanding careful consideration of a range of factors to optimize time, cost, safety, scalability, and environmental impact. A well-chosen synthesis route not only facilitates efficient drug development but also contributes to the overall success and sustainability of pharmaceutical manufacturing. The infographic covers five points to consider and their importance in pharmaceutical route scouting.

Safety, efficiency and expertise define our high-potent drug manufacturing capabilities. Our dedicated facility not only manufactures high-potent APIs at the pilot stage, but also at a commercial scale. In total, >300KL high potent manufacturing capacity is available at Laurus. #LaurusSynthesis #innovation #drugdevelopment #drugmanufacturing #biotech #pharmaceutical #pharmaceuticalmanufacturing #cdmo   #apimanufacturing #HighPotentDrugManufacturing

The Covid- 10 pandemic will not be the last one, we could face crisis equally or more severe in the future. Pharmaceutical companies must be prepared for similar discruptions and ensure the innovation enfine runs at full speed. Digital is a catalyst in allowing the transformation of the entire drug development supply chain, in shortening the clinical trial timelines and in bringing new drugs to the market. Take a dive and discover more. Go to: https://lnkd.in/gXfRfUG9

AlphaBio Inc. News We're thrilled to announce the reboot of Alphabio.com in the Intermountain West Region, as a trusted partner in innovation for Pharma 4.0 and beyond. At Alphabio, we're dedicated to solving industry-wide challenges, driving innovation, and delivering best-in-class products to the pharmaceutical, biotech and fluid management industries. Our commitment to precision and excellence is at the core of everything we do, from best in class products to elegant system design. Watch this space for upcoming product launches, groundbreaking innovations, and market-impactful updates. We're excited to embark on this new chapter and journey with you to redefine the future of biotech, pharma, and single use components. Stay tuned for more! 🚀 #Alphabio #Innovation #Biotech #Pharmaceuticals #FluidManagement #abundanceinmedicine #Pharma4.0 #LifeSciences #singleusetechnology #GMP #Alphinity #Consynsys #Aquasyn #disruptivetechnologies #upstreamprocessing #downstreamprocessing